Repurposing Drugs for Breast Cancer

Applying the dashboard based selection methods described in the prediction of BrCa activity section upon prescription drugs we have created unique drug target pairs with average scores per pair: the already described BrCaScore and the chemblScore which shows the effect that the molecule average score for each particular target.

The graph below shows BrCaScore vs chemblScore. Marked dots are displayed on the right side showing the targets where the drugs have an activity record,  and the value, in bars of their potency at target compared to the potency inhibiting BrCa cell lines growth. There is also a 3rd blue bar showing the predicted cytotoxicity from the cytotox prediction section. Left chart is splitted in three boxes, depending on the drugs have indications for breast cancer, any indication for tumor treatment, or lack of any indication for tumoral diseases. For repurposing, we will focus on the 3rd group. Marked dots are those of the highest potency in the two scores.

And here, most potent at target and a score >6 for BrCa…

Below, most potent at BrCa and a score >6 for each target…

Finally, we can look at this treemap showing the clinical phase achieved by the drugs, current indications, published MoAs and colored by their potency inhibiting BrCa cell lines growth.

BrCa is one of the most investigated diseases, so it should not be weird to find literature references that associate some of these drugs toBrCa, as it can be seen in the table below.

Even more interesting, the drugs have activity records for several targets, and mos of them count with literature references that associate them to BrCa.